HOMA-IR Explained: How to Measure Insulin Resistance at Home

Here’s a scenario I’ve seen play out more times than I can count: a patient comes in with a hemoglobin A1c of 5.6% — technically “normal,” but sitting right at the top of the range. Their fasting glucose is 98. Their doctor tells them everything looks fine. Come back in a year.

What no one checked was their fasting insulin. If it had been checked — and if someone had done the 30 seconds of math required to calculate their HOMA-IR — they might have discovered that this patient has had significant insulin resistance for the better part of a decade. That insulin resistance is quietly driving weight gain they can’t explain, fatigue they’ve written off as aging, and a metabolic trajectory that, left uninterrupted, ends in a type 2 diabetes diagnosis in five to seven years.

HOMA-IR is not a complicated test. It’s not expensive. And it is one of the most clinically useful numbers you can have about your own metabolic health. The reason most people have never heard of it comes down to a single problem: routine bloodwork almost never includes a fasting insulin level, which means the calculation never gets done.

What Is HOMA-IR?

HOMA-IR stands for Homeostatic Model Assessment of Insulin Resistance. It was developed in 1985 by Matthews and colleagues at Oxford as a mathematical model to estimate insulin resistance and beta-cell function from a single fasting blood sample. Despite being developed four decades ago, it remains one of the most validated and widely used measures of insulin resistance in clinical research and, increasingly, clinical practice.

The concept behind it is straightforward. In a healthy metabolic state, a relatively modest amount of insulin is sufficient to keep fasting blood glucose in a normal range. As your cells become resistant to insulin’s signal, the pancreas has to produce more and more insulin to maintain the same blood glucose level. HOMA-IR captures this relationship — high insulin paired with even nominally normal glucose is the signature of early insulin resistance.

The Formula

HOMA-IR is calculated as:

HOMA-IR = (Fasting Insulin [µIU/mL] × Fasting Glucose [mg/dL]) ÷ 405

If your lab reports glucose in mmol/L, the denominator changes to 22.5.

That’s it. Two lab values, one division. The result is a dimensionless number that reflects the degree of insulin resistance.

How to Interpret Your HOMA-IR Score

There is no single universal cutoff because HOMA-IR values vary slightly across populations, insulin assay platforms, and laboratories. That said, the clinical literature has converged on a reasonably consistent set of thresholds:

HOMA-IR Score	Interpretation
< 1.0	Optimal insulin sensitivity
1.0 – 1.9	Normal range; some variance by age and population
2.0 – 2.9	Borderline; early insulin resistance likely
≥ 3.0	Clinically significant insulin resistance
≥ 5.0	Severe insulin resistance; often associated with metabolic syndrome, MASLD, or pre-diabetes

A few important nuances:

Age matters. HOMA-IR tends to rise slightly with age even in otherwise healthy adults. A score of 2.2 in a 55-year-old is less alarming than the same score in a 28-year-old.

Context matters more than the number. A HOMA-IR of 2.5 in someone who is lean with no other metabolic risk factors is a different clinical picture than the same score in someone with a 42-inch waist, elevated triglycerides, and low HDL.

Trend over time is valuable. A single HOMA-IR measurement is useful; serial measurements over 2–3 years tell you whether your metabolic trajectory is improving or deteriorating. If you implement lifestyle changes and your HOMA-IR drops from 3.1 to 1.6, that’s a concrete, quantifiable measure of improvement.

Clinical Callout: HOMA-IR is not a diagnostic criterion for diabetes or pre-diabetes — those diagnoses use fasting glucose, HbA1c, or oral glucose tolerance test (OGTT) criteria per ADA guidelines. What HOMA-IR gives you is something those tests often miss: the physiologic state that precedes those diagnoses by years. Insulin resistance can be present and clinically meaningful a decade before your fasting glucose ever crosses the 100 mg/dL threshold.

Why Standard Labs Miss This

The reason HOMA-IR is so rarely calculated in clinical practice is simple: most standard metabolic panels don’t include fasting insulin.

A standard CMP (comprehensive metabolic panel) gives you fasting glucose. A hemoglobin A1c tells you your average glucose over approximately three months. Neither tells you anything about insulin levels. You could have a fasting glucose of 92 and an HbA1c of 5.3 — both reassuringly normal — while your pancreas is pumping out three to four times the normal amount of insulin to achieve those numbers. That hyperinsulinemia is invisible to standard testing, but it has real consequences: it drives visceral fat deposition, elevates triglycerides, promotes inflammation, and is independently associated with cardiovascular disease.

The reason fasting insulin isn’t routinely ordered is a combination of cost (it’s a slightly more expensive test than glucose), historical clinical inertia, and the fact that hyperinsulinemia in the absence of overt hyperglycemia has no approved pharmacologic treatment that most PCPs would prescribe. The logic — unstated but pervasive — is that if you can’t drug it, why measure it?

I disagree with that logic fundamentally. Identifying insulin resistance early gives you a window to intervene with lifestyle changes that work far better before the pancreatic beta cells have been under chronic stress for years. Prevention is more effective than treatment.

How to Order the Test Yourself

You do not need a physician referral to test your HOMA-IR. You need two tests:

1. Fasting insulin (also called serum insulin)
2. Fasting glucose (available standalone or as part of a CMP)

Both must be drawn in a fasted state — minimum 8 hours, ideally 10–12 hours without caloric intake. Water is fine. Coffee without cream or sugar is debatable but best avoided on test day.

Several direct-to-consumer lab platforms — including Ulta Lab Tests, Walk-In Lab, and Marek Diagnostics — allow you to order these tests directly online, then visit a local LabCorp or Quest draw site. Combined cost is typically $30–60 without insurance. Function Health includes fasting insulin as part of their comprehensive panel.

Once you have both numbers, the math takes 30 seconds:

Example: Fasting insulin = 12 µIU/mL, Fasting glucose = 94 mg/dL HOMA-IR = (12 × 94) ÷ 405 = 2.79 → Borderline insulin resistance

Example: Fasting insulin = 4 µIU/mL, Fasting glucose = 88 mg/dL HOMA-IR = (4 × 88) ÷ 405 = 0.87 → Excellent insulin sensitivity

What Conditions Are Associated With Elevated HOMA-IR?

Insulin resistance is not just a precursor to diabetes. It is a central metabolic dysfunction that underlies or accelerates a surprisingly wide range of conditions:

Type 2 diabetes and pre-diabetes. The most direct relationship. Insulin resistance is the primary pathophysiologic driver of type 2 diabetes; elevated HOMA-IR is one of the strongest predictors of progression from normoglycemia to pre-diabetes and from pre-diabetes to overt T2DM.

Metabolic-associated steatotic liver disease (MASLD, formerly NAFLD). Insulin resistance drives hepatic fat deposition. HOMA-IR is one of the best non-invasive markers of liver fat burden and is used clinically to monitor treatment response.

Polycystic ovarian syndrome (PCOS). The majority of women with PCOS — regardless of body weight — have measurable insulin resistance, which is a key driver of androgen excess and anovulation in the condition. HOMA-IR testing is particularly useful in lean women with PCOS who might otherwise be dismissed as “normal weight” and therefore not metabolically at risk.

Cardiovascular disease. Hyperinsulinemia promotes dyslipidemia (high triglycerides, low HDL), hypertension, endothelial dysfunction, and atherosclerosis. HOMA-IR predicts incident cardiovascular events independently of traditional risk factors.

Cognitive decline. Emerging research has linked insulin resistance — sometimes called “type 3 diabetes” in the neuroscience literature — to Alzheimer’s disease pathogenesis. Insulin signaling plays a role in neuronal glucose metabolism and amyloid clearance.

Clinical Callout: One of the most clinically underrecognized manifestations of insulin resistance is dyslipidemia — specifically the combination of elevated triglycerides, low HDL, and small dense LDL particles. If your lipid panel shows this pattern but your fasting glucose is normal, check your fasting insulin. The driving force is frequently insulin resistance, not dietary fat intake.

What Drives Insulin Resistance in the First Place?

Understanding the causes helps frame the interventions:

Visceral adiposity. Visceral fat (the fat packed around your organs, not subcutaneous fat under the skin) is metabolically active in a harmful way. It releases free fatty acids and inflammatory cytokines that directly impair insulin signaling in muscle and liver.

Physical inactivity. Skeletal muscle is the primary site of insulin-mediated glucose uptake. Inactivity reduces GLUT4 transporter expression in muscle cells, impairing their ability to respond to insulin.

Chronic sleep deprivation. Even a few nights of poor sleep acutely elevates HOMA-IR. Sleep is not optional for metabolic health.

Dietary pattern. Chronically elevated caloric intake — particularly from highly processed carbohydrates and fructose — drives persistent postprandial insulin secretion and, over time, receptor downregulation.

Chronic stress. Cortisol is catabolic and directly antagonizes insulin signaling. Chronic psychological or physiologic stress is a meaningful contributor to insulin resistance that is frequently overlooked.

How to Lower Your HOMA-IR

The good news is that insulin resistance is among the most responsive metabolic conditions to lifestyle intervention.

Resistance Training

Resistance training is the single most effective lifestyle intervention for improving insulin sensitivity, and in my view it’s underemphasized relative to aerobic exercise. Muscle is the body’s primary glucose disposal unit. Building and maintaining muscle increases the pool of GLUT4 transporters available for insulin-mediated glucose uptake — both during and up to 48 hours after a training session. Three to four sessions per week of progressive resistance training can produce meaningful improvements in HOMA-IR within 6–8 weeks.

Low-Carbohydrate or Ketogenic Diets

Reducing carbohydrate intake directly reduces postprandial insulin secretion, giving the insulin signaling system a chance to resensitize. Multiple randomized trials have shown that low-carbohydrate diets reduce HOMA-IR more effectively than low-fat diets matched for calories. This doesn’t mean carbohydrates are inherently toxic — but for someone with elevated HOMA-IR, reducing carbohydrate load is one of the fastest dietary interventions to reduce insulin burden.

Time-Restricted Eating (TRE)

Eating within a compressed window — typically 8–10 hours — reduces the duration of daily insulin secretion and allows for extended periods of low insulin during the fasting window. The evidence on TRE improving HOMA-IR is solid, particularly when the eating window is aligned with earlier in the day rather than later.

Aerobic Exercise

Zone 2 cardio — sustained moderate-intensity aerobic exercise at roughly 60–70% of max heart rate — improves mitochondrial function and fat oxidation in skeletal muscle, both of which support insulin sensitivity. Aim for 150+ minutes per week.

Sleep Optimization

Prioritizing 7–9 hours of quality sleep has a measurable impact on insulin sensitivity. If you have untreated obstructive sleep apnea, treating it can dramatically improve metabolic markers.

Pharmacologic Options

For patients with significant insulin resistance who haven’t responded adequately to lifestyle intervention:

Metformin remains the first-line pharmacologic option. It reduces hepatic glucose production and has modest beneficial effects on insulin sensitivity. It’s inexpensive, has decades of safety data, and is increasingly used off-label for metabolic optimization in non-diabetic patients.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce substantial reductions in HOMA-IR, largely through weight loss and reduced caloric intake. In patients with significant metabolic dysfunction, these agents can break the cycle of hyperinsulinemia and visceral fat accumulation in ways that lifestyle alone often cannot.